Revolution Medicines is trading at $208.02 (+4.17%) in pre-market after its November 4 earnings report showed RASONQUE generated $197.6 million in roughly five weeks of U.S. sales.
- Quarterly revenue beat estimates; the company reported a $407.5 million net loss and reiterated 2026 operating-expense guidance.
- Management cautioned early sales included finite patient cohorts and initial channel stocking, which may not indicate the longer-term launch trajectory.
- Biotech gained 2.08% pre-market, supportive context but not the primary explanation.